Business Context and Reporting Period
This Form 6-K filing by Inventiva S.A. covers the month of May 2025, specifically reporting on the execution of the "T2 Transaction" on May 2, 2025. Inventiva is a clinical-stage biopharmaceutical company focused on the development of lanifibranor for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The company has no approved products and has not generated product revenue to date.
Key Financial Metrics
The filing details a significant capital raise but does not provide historical revenue, profit, or cash flow statements for the period.
- Gross Proceeds: €115.6 million from the T2 Transaction.
- Net Proceeds: €108.5 million.
- Securities Issued: 42,488,883 ABSAs (Attached Share-Based Awards) at €1.35 per unit and 43,437,036 T2 PFW-BSAs (Pre-Funded Warrant-Based Awards) at €1.34 per unit.
- Warrant Terms: Each unit includes a warrant to purchase 0.9 ordinary shares at an exercise price of €1.50 per share (€1.35 per warrant). Maturity date is July 30, 2027.
- Warrant Condition: Exercise is contingent on the release of topline data by June 15, 2027, confirming that Key Primary or Secondary Endpoints in the Phase 3 NATiV3 trial are met.
Material Changes
The primary material change is the completion of the second tranche of a multi-tranche private placement previously announced in October 2024. This transaction significantly increases the company's cash reserves compared to prior periods, enabling the continuation of its clinical development program. The filing notes that the T2 Securities are expected to be issued on May 7, 2025, subject to closing conditions.
Outlook, Management Commentary, and Risks
Use of Proceeds: Management intends to use the net proceeds, alongside existing cash, to finance the NATiV3 Phase 3 trial until results publication and to initiate a compensated cirrhosis study.
Forward-Looking Statements: The filing contains extensive forward-looking statements regarding the timing of the NATiV3 trial results, regulatory approvals, and commercialization. Management cautions that actual results may differ materially due to various risks.
Key Risks and Contingencies:
- Clinical Uncertainty: No guarantee that clinical trial results will be available on the anticipated timeline or that endpoints will be met.
- Safety Concerns: Reference to a previously announced Suspected Unexpected Serious Adverse Reaction (SUSAR) which could impact trial results or timing.
- Financial Viability: The company has incurred significant losses since inception and requires additional capital to continue operations; failure to secure funding could lead to curtailment of programs or inability to continue as a going concern.
- Regulatory and Market Risks: Risks include regulatory holds, failure to demonstrate safety/efficacy, patient recruitment challenges, and macroeconomic factors including geopolitical conflicts and inflation.
Investor Verification Checklist
- Verify the final closing date and actual issuance of the T2 Securities (expected May 7, 2025).
- Confirm the specific impact of the previously announced SUSAR on the NATiV3 trial timeline and design.
- Monitor the release of topline data for the NATiV3 trial by the June 15, 2027 deadline, which is a condition for warrant exercise.
- Review the company's cash burn rate and runway to assess if the €108.5 million net proceeds are sufficient to reach the next major milestone without further dilution.
- Check for any updates on the "compensated cirrhosis study" initiation timeline.